The estimated Net Worth of Robert Azelby is at least $2.02 Million dollars as of 17 June 2024. Robert Azelby owns over 6,995 units of ADC Therapeutics SA stock worth over $155,835 and over the last 8 years Robert sold ADCT stock worth over $1,861,131.
Sign up
Robert Azelby ADCT stock SEC Form 4 insiders trading
Robert has made over 11 trades of the ADC Therapeutics SA stock since 2016, according to the Form 4 filled with the SEC. Most recently Robert sold 6,995 units of ADCT stock worth $20,216 on 17 June 2024.
The largest trade Robert's ever made was exercising 102,539 units of ADC Therapeutics SA stock on 22 January 2018 worth over $5,307,419. On average, Robert trades about 6,374 units every 90 days since 2016. As of 17 June 2024 Robert still owns at least 53,005 units of ADC Therapeutics SA stock.
You can see the complete history of Robert Azelby stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert Azelby's mailing address?
Robert's mailing address filed with the SEC is 430 MOUNTAIN AVENUE, SUITE 404, , NEW PROVIDENCE, NJ, 07974.
Insiders trading at ADC Therapeutics SA
Over the last few years, insiders at ADC Therapeutics SA have traded over $225,811 worth of ADC Therapeutics SA stock and bought 800,000 units worth $2,248,000 . The most active insiders traders include Ron Squarer, Victor Sandor, and Group, Llc Green Jeremy Red.... On average, ADC Therapeutics SA executives and independent directors trade stock every 6 days with the average trade being worth of $281,514. The most recent stock trade was executed by Group, Llc Green Jeremy Red... on 1 July 2024, trading 800,000 units of ADCT stock currently worth $2,248,000.
What does ADC Therapeutics SA do?
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
What does ADC Therapeutics SA's logo look like?
Complete history of Robert Azelby stock trades at Clovis Oncology Inc, Immunomedics, Cardinal Health, and ADC Therapeutics SA
ADC Therapeutics SA executives and stock owners
ADC Therapeutics SA executives and other stock owners filed with the SEC include:
-
Dr. Michael Mulkerrin,
Head of Chemistry Manufacturing & Control and VP -
Dr. Patrick van Berkel,
Sr. VP of R&D -
Kimberly Pope,
Sr. VP & Chief HR Officer -
Dr. Peter Greaney Ph.D.,
Head of Corp. Devel. -
Susan Romanus,
Chief Compliance Officer -
Amanda Hamilton,
Investor Relations Officer -
Robert A. Schmidt,
VP, Corp. Controller & Chief Accounting Officer -
Jennifer Creel,
Chief Financial Officer -
Michael Forer L.L.B.,
Vice Chairman, Exec. VP & Gen. Counsel -
Dr. Christopher J. Martin Ph.D.,
Co-Founder, CEO & Director -
Ron Squarer,
Director -
Viviane Monges,
Director -
Thomas Pfisterer,
Director -
Victor Sandor,
Director -
Peter Hug,
Director -
Jean Pierre Bizzari,
Director -
Robert Azelby,
Director -
Group, Llc Green Jeremy Red...,
-
Ameet Mallik,
Chief Executive Officer